Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

NCT07215520 PHASE2 RECRUITING

A Double-blind, Randomized, Controlled, Phase 2a Study to Evaluate the Safety and Tolerability of a Newcastle Disease Virus-based Mucosal Vaccine (NDV-HXP-S-KP.2) Relative to an Approved Systemic mRNA Vaccine in Previously Vaccinated Adults

Details

Lead sponsor	CastleVax Inc.
Phase	PHASE2
Status	RECRUITING
Enrolment	200
Start date	Mon Nov 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Aug 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• COVID-19

Interventions

• NDV-HXP-S-KP.2
• COVID-19 mRNA Vaccine

Countries

United States